Revvity Says AI Demand Is Spreading Past Screening, Holds Detail For Its November 13 Investor Day

Revvity guides fourth-quarter organic growth to about 5%, down from 7% in the third, as its CEO calls AI demand "very early days."

Share
Revvity Says AI Demand Is Spreading Past Screening, Holds Detail For Its November 13 Investor Day

Revvity CEO Prahlad Singh said on the company's third-quarter earnings call Tuesday that AI-related demand is starting to reach products beyond high content screening, but management held back sizing it until an investor day on November 13. The company guided fourth-quarter organic growth to about 5%, against 7% in the third quarter.

AI demand: early, and broadening

Revvity, which makes the instruments, reagents (the materials used in lab tests), software and services used by researchers and clinical labs, said AI demand was first concentrated in high content screening. Singh said it is now showing up across a wider slice of the portfolio, but is "still in its very early days." He said customers are "only beginning to scratch the surface" of how AI is reshaping their workflows.

Pressed by an Evercore ISI analyst on which products are exposed and what share of revenue, Singh described a path from high content screening to high throughput screening, then imaging and in vivo, with a broader impact across preclinical products expected in 2027. A Leerink Partners analyst asked for order-book metrics. Singh said high content screening backlog rose in the third quarter and revenue growth accelerated despite strong year-ago comparisons, but "I don't think we are going to start quantifying" subsegments.

CFO Max Krakowiak said backlog across the instrument portfolio grew "across almost every instrument group." Instruments grew strong mid single digits in the third quarter, and management expects high single digits in the fourth.

Why the fourth quarter steps down

Third-quarter revenue was $710 million, with pro forma organic growth of 7% and adjusted earnings per share of $1.37. Full-year pro forma organic growth is now expected at about 5%, with adjusted EPS of $5.40 to $5.45.

Asked by the Evercore ISI analyst why the fourth quarter slows, Krakowiak named two factors in life sciences. Reagents slow from high single digits to mid single digits as about 100 basis points of bulk screening orders, which landed in the third quarter, drop out. Software growth moderates toward the mid-teens from the upper teens.

Krakowiak said those bulk orders had been planned for the fourth quarter. The reagent outlook for that quarter is unchanged at mid single digits.

Saving the details for investor day

Asked by an RBC Capital Markets analyst about uptake of new software products, Singh said he did not want to "burst their bubble" before the investor day. Krakowiak told a Barclays analyst he did not want to give "too much of a spoiler." He did say software annualized portfolio value grew double digits again and is on track to do so for the year.

On Genomics England, Krakowiak said Revvity is now embedding about $25 million in full-year revenue, with negotiations under way to extend and expand the partnership.

Singh called the quarter the first full demonstration of the company's potential since its recent transformation, after a year that began with an outlook of 2% to 3% organic growth. Krakowiak said conditions have been improving since mid-February. Revvity's market value was $16.9 billion as of Tuesday morning.

Revvity's investor day is in New York on November 13, where management said it will cover AI's effect on science, its software business and considerations for 2027.

Sources